Chronic neuropathic pain may be caused, in part, by loss of inhibition in spinal pain processing pathways due to attenuation of local GABAergic tone. Nociception and nocifensive behaviors are reduced after enhancement of tonically activated extrasynaptic GABA A R-mediated currents by agonist ligands for d subunit-containing GABA A Rs. However, typical ligands that target d subunit-containing GABA A Rs are limited due to sedative effects at higher doses. We used the spinal nerve ligation (SNL) and gp120 models of experimental neuropathic pain to evaluate compound 2-261, a nonbenzodiazepine site positive allosteric modulator of a 4 b 3 d GABA A Rs optimized to be nonsedative by selective activation of b 2/3 -subunit-containing GABA A Rs over receptor subtypes incorporating b 1 subunits. Similar levels of 2-261 were detected in the brain and plasma after intraperitoneal administration. Although systemic 2-261 did not alter sensory thresholds in sham-operated animals, it significantly reversed SNL-induced thermal and tactile hypersensitivity in a GABA A R-dependent fashion. Intrathecal 2-261 produced conditioned place preference and elevated dopamine levels in the nucleus accumbens of nerve-injured, but not sham-operated, rats. In addition, systemic pretreatment with 2-261 blocked conditioned place preference from spinal clonidine in SNL rats. Moreover, 2-261 reversed thermal hyperalgesia and partially reversed tactile allodynia in the gp120 model of HIV-related neuropathic pain. The effects of 2-261 likely required interaction with the a 4 b 3 d GABA A R because 2-301, a close structural analog of 2-261 with limited extrasynaptic receptor efficacy, was not active. Thus, 2-261 may produce pain relief with diminished side effects through selective modulation of b 2/3 -subunit-containing extrasynaptic GABA A Rs.
Introduction
Few therapies with novel mechanisms of action have been introduced to clinical practice for pain. 45 Poor overall efficacy of available medications is reflected by high numbers-needed-totreat values. 14, 42, 46, 65 Nonsteroidal anti-inflammatory agents often have limited efficacy in chronic pain. 13, 37 Opioid use for the treatment of chronic nonmalignant pain remains uncertain due to questionable efficacy 37 and serious toxicity including lethal respiratory depression, somnolence, constipation, hyperalgesia, tolerance, dependence, and addiction that collectively diminish quality of life. 21 Thus, targeting a nonopioid receptor intimately involved in pain with decreased abuse and addiction liability would be highly significant. 19 Gamma-aminobutyric acid A receptors (GABA A Rs) have long been hypothesized to represent targets for pain therapeutics. 28 GABA A Rs are complex heteropentameric proteins formed by 2 a, 2 b, and one g subunit 61, 63 that function to hyperpolarize neurons and inhibit neurotransmission through chloride ion influx. Diminished synaptic and/or extrasynaptic inhibition at spinal GABA A Rs promotes enhanced network excitability that sustains chronic pain. 26, 27, 69 It has been reported that the expression of GABA A R d subunits and the GABAergic tonic current decreased in substantia gelatinosa neurons after chronic constriction injury in mice and that enhancement of d subunits-containing GABA A receptors in the spinal cord dorsal horn neurons attenuated acute nociception, blocked long-term potentiation, and inhibited formalin-induced spontaneous pain. 27, 41 Recently, de Koninck et al. demonstrated that downregulation of spinal KCC2 potassium chloride cotransporters results in loss of the electrochemical chloride gradient in states of experimental chronic pain. 9 Therefore, restoration of spinal inhibitory control is hypothesized to be analgesic. 16, 74 Thalamic GABA A R isoforms are also associated with the processing of pain signals. 44, 51, 62 The thalamus exhibits both phasic and tonic GABAergic inhibitory mechanisms through GABA projections to sensory relay neurons, originating sensory nuclei or the thalamic reticular nucleus (Rt). 44, 62 Microinjection of the GABA A R antagonist picrotoxin into the ventrobasal thalamus complex in rats results in pain-like behavior. 51 Immunohistological studies indicate robust expression of a 4 , b 2 , and d GABA A R subunits in the thalamus. 30, 53 Gaboxadol, a a 4 bd subtypeselective agonist, is analgesic in animals and humans, 1, 18, 36, 38, 39, [57] [58] [59] suggesting that activation of a 4 bd GABA A Rs may contribute to the reduction in pain.
We previously reported a series of nonbenzodiazepine (BZ) site enaminone positive allosteric modulators (PAMs) that show preference for b 2/3 -expressing GABA A Rs as promising therapies for anxiety. 17, 24 The unique GABA mechanism of b 2/3 -preferring compounds suggests that these compounds could modulate pain states in a therapeutically superior manner compared with currently prescribed GABA A R PAMs (ie, BZs). Here, we report 2-261, a nonsteroidal small molecule b 2/3 -subunit-preferring PAM, evokes robust positive modulation at BZ-insensitive a 4 b 3 d GABA A Rs to mitigate chronic pain states.
Methods

Two-electrode voltage-clamp electrophysiology
Two-electrode voltage-clamp recordings were made 3 to 14 days after mRNA injections of isoforms of human GABA A R ab or abd subunits at a holding voltage of 270 mV using electrophysiological procedures that were previously described. 24 The GABA recordings were performed in standard Ringer, and drug/wash solutions were applied through a microcapillary "linear array" that enables subsecond application of agonists. Currents were recorded on a PC-based computer (PClamp 9.0; Molecular Devices, Sunnyvale, CA). All compounds were tested with a 30-second pretreatment before coapplication with EC 10 GABA (concentration of GABA that evokes 10% of the maximum response) for the control response. The GABA EC 10 was determined in each individual oocyte expressing the receptor subtype of interest. Percent modulation of the GABA EC 10 by the modulator was calculated as: {([I GABA EC10 1 modulator /I GABA EC10 ] 3 100) 2 100}. A 4-parameter logistic equation (GraphPad Software, San Diego, CA) was used to fit concentration-effect data.
Animals
Adult, male Sprague-Dawley rats (250-350 g; Envigo, Indianapolis, IN) were used. The experiments followed the guidelines of the Committee for Research and Ethical Issues of IASP. All procedures were approved by the University of Arizona Institutional Animal Care and Use Committee. Rats were housed 3 per cage on a 12-hour light-dark cycle (lights on at 7 AM) with food and water ad libitum. After intrathecal (i.t.) catheterization or intracranial cannulation, animals were housed individually. All behavioral studies were performed by experimenters blinded to the experimental groups and treatments.
L5/L6 spinal nerve ligation
Lumbar 5 and 6 spinal nerves were ligated according to Ref. 34 . Briefly, 5% and 2% isoflurane delivered in air at 1 L/min were used for initiation and maintenance of anesthesia. L 5 /L 6 were tightly ligated with 4-0 silk suture using the aseptic procedure. The animals were returned to their home cages for recovery for 12 to 14 days. Sham surgeries were performed similarly without ligation of the spinal nerves. The health of the animals was monitored closely and any that demonstrated motor deficits or failed to develop tactile or thermal hypersensitivity after nerve injury were excluded from further testing; 6 to 8 animals were used per group.
HIV-related neuropathic pain
HIV-related neuropathic pain was induced with spinal administration of the HIV envelope protein gp120 (300 ng/20 mL/rat, i.t.) injected every other day for 3 days (ie, at days 1, 3, and 5) according to published reports 72 ; 5 to 6 animals were used per group.
Nucleus accumbens' cannulation
Stereotaxic surgeries were performed as previously published. 67 Rats were anesthetized with ketamine/xylazine 80/12 mg/kg, intraperitoneally (i.p.) (dissolved in normal saline; Western Medical Supply, Arcadia, CA/Sigma, St. Louis, MO). A single guide cannula (AG-8; EICOM, San Diego, CA) was implanted into the left nucleus accumbens (NAc) shell using the co-ordinates determined by a rat brain atlas (Paxinos and Watson, 6th Edition): anteroposterior: bregma 11.7 mm; medial lateral: midline 2 1.0 mm; and dorsoventral: skull 2 6.0 mm. Rats were allowed to recover for 7 days individually after surgery. Data from animals with incorrect cannula placements were discarded by post hoc histological verification.
Intrathecal catheterization
The animals were anesthetized by ketamine/xylazine (80/12 mg/ kg, i.p.) anesthesia, and i.t. catheters (polyethylene 10, 7.5 cm) were inserted through the atlanto-occipital membrane with the catheter tip positioned slightly rostral to the lumbar spinal cord as described previously. 67 Animals were housed individually afterwards and allowed to recover for at least 7 days. Rats with motor deficits were euthanized. Intrathecal injection volumes were a 5 (drug) or 20 (gp120) mL of treatment solution plus a 0.5-mL air bubble and a 10-mL saline flush.
Evaluation of tactile thresholds and thermal latencies
The paw withdrawal threshold was evaluated using calibrated von Frey filaments (Stoelting, Wood Dale, IL) ranging from 0.41 to 15 g (4-150 N) to probe the plantar surface perpendicularly in a Dixon "up and down" fashion as described previously. 6, 11, 35, 68 Antiallodynic effects were calculated as (Postdose threshold 2 Predose threshold)/(Baseline 2 Predose threshold) 3 100. For thermal hyperalgesia, paw withdrawal latency was evaluated using Hargreaves' analgesia meter with an infrared radiant heat source as previously described. 5, 48, 66 Rats were acclimated to the Plexiglas chambers for 30 minutes, and the left hind paws were tested. The intensity of the heat stimulus was determined initially to set the baseline latencies at approximately 20 seconds. A maximal cutoff of 33 seconds was used to prevent tissue damage. Antihyperalgesic effects were calculated as (Postdose latency 2 Predose latency)/(Baseline 2 Predose Latency) 3 100.
Conditioned place preference procedures
We used the single-trial-conditioning protocol for conditioned place preference (CPP) as previously described. 35, 40, 48 Briefly, on baseline (day 1) and testing (day 3) days, rats were allowed to explore all 3 CPP chambers that had distinct olfactory, tactile, and visual cues for 15 minutes. Any-maze (Stoelting) was used to record the time spent in each chamber. The animals were counterbalanced based on their baseline results to prevent preconditioning bias. Two pairings were done on the conditioning day (day 2, 14 days after spinal nerve ligation [SNL] ). In the morning, rats received a vehicle injection (5 mL, i.t.) and paired with the assigned chamber for 30 minutes. Four hours later, rats received 2-261 (0.2 mg/5 mL, i.t. injection) and were paired with the opposite chamber for 30 minutes. Difference scores were calculated as test time subtracted by baseline time in the drugpaired chamber. Animals with biased baseline (ie, ,20% or .80% of time spent in one chamber on day 1) were excluded from further test. In addition, data from animals that showed no, or low, levels of exploration on the test day (,10 seconds spent in 2 of the 3 chambers on day 3) were excluded from the data analysis.
Separate groups of rats were tested for the blockade of i.t. clonidine (10 mg)-induced CPP by pretreatment of systemic 2-261 (10 mg/kg, i.p.) in SNL rats. The procedures were same as described above except that during the conditioning day, the animals were pretreated with vehicle (1 mL/kg, i.p.) followed 30 minutes later by i.t. injection of saline (5 mL) and then immediately paired with one chamber. In the afternoon, the animals received 2-261 (10 mg/kg, i.p.) followed 30 minutes later by i.t. clonidine (10 mg/5 mL) administration and then were immediately paired with the other chamber. Nine to 16 animals were used for SNL and sham-operated groups.
In vivo microdialysis and HPLC quantification of dopamine
Microdialysis was performed in awake, freely moving animals as described previously. 48, 67 The microdialysis probe (AI-8-2; EICOM) with semipermeable membrane (MW cutoff: 20 kDa) was inserted into the NAc through the guide cannula with a 2-mm protrusion to pass beyond scar tissue. Artificial cerebrospinal fluid (147.0 mM NaCl, 2.8 mM KCl, 1.2 mM MgCl 2 , and 1.2 mM CaCl 2 ) was perfused at 1.25 mL/min, and 30-minute fractions were collected into cold (4˚C) amber Eppendorf tubes prefilled with 1.0 mL 403 antioxidant solution (6.0 mM L-cysteine, 2.0 mM oxalic acid, and 1.3% wt/vol glacial acetic acid). 25 After a 90-minute washout period, 2 baseline and 4 treatment fractions (30 min/ fraction) plus 2 positive control fractions after cocaine (20 mg/kg, i.p.) injection were collected.
All fractions were analyzed using liquid chromatography (Agilent 1100 HPLC equipped with a 5020 guard cell [set at 350 mV] and a MD-150 column) with an electrochemical detector (Coulochem III 5014B, Electrode1 set at 2150 mV, and Electrode2 at 250 mV; Thermofisher, Waltham, MA) at ambient temperature. The limit of detection and limit of quantification were calculated to be 0.286 and 0.868 pg, respectively, from 6 serial dilutions of dopamine (DA) standard (1.25-40 pg). The integration of the DA peaks from HPLC chromatograms was performed by an experimenter blinded to the treatment groups.
To compare the results from different groups of animals, we calculated percent change from baseline values. The accumulated area under the time effect curve was also calculated. Data from rats with extremely low basal DA levels (below limit of quantification), misplaced cannula, uneven baselines (.50% difference in DA concentrations between the 2 baseline fractions), or lack of sufficient increase of extracellular DA after cocaine injections (,100% over baseline) were excluded from data analysis. The group size for Sham/Vehicle, Sham/2-261, SNL/Vehicle, and SNL/2-261 was 4, 7, 10, and 15, respectively.
Drug administration
2-261 and analogs were synthesized as previously described 24 and dissolved in 10% dimethyl sulfoxide and 90% saline. Allopregnanolone was synthesized as previously described. 55 Gabazine was purchased from Sigma Aldrich (St. Louis, MO). Clonidine hydrochloride (Tocris, Ellisville, MO) and cocaine (obtained from NIDA) were dissolved in saline (0.9% NaCl). Gp120 (SPEED BioSystems, Gaithersburg, MD) was dissolved in 0.1% bovine serum albumin in 0.1 M phosphate-buffered saline at 15 ng/mL final concentration. 72 The dose volume for i.p. injections was 1 mL/kg, unless specified otherwise.
Pharmacokinetic studies of 2-261
Pharmacokinetic analysis was performed as previously described. 70 Briefly halothane-euthanized animals received cardiac puncture at various time points after 2-261 administration. Plasma in blood samples was separated by centrifugation at 1000 3 g for 6 minutes. Rat brains were removed after perfusion with saline. Brain and plasma samples were stored at 220˚C until processed for extraction and analysis. Brain samples (;0.1 g) were combined with 1 mL of phosphate-buffered saline (pH 7.4) and homogenized and combined with 1 mL 1-029 (10 mg/mL) as internal standard.
33 0.5-mL ethyl acetate was used to extract brain samples. 0.5-mL acetonitrile was used to extract plasma samples also combined with 1 mL 1-029 (10 mg/mL). Brain and plasma extract/solvent mixtures were spun 1000 3 g for 10 minutes. The decanted plasma and brain extraction supernatants were evaporated to dryness. Samples were resuspended in 100 mL of acetonitrile, vortexed, and pipetted to sample tubes. Plasma and brain samples were acquired through a Shimadzu SIL-HTc autosampler, run through a C18 column (Poroshell 120 EC-C18 4.6 3 50 mm, 2.7 mM; Agilent Technologies, Santa Clara, CA) using a Shimadzu LC-10ADvp HPLC via a 90% acetonitrile/10% H 2 O mobile phase and multiple reaction monitoring on a Quattro Premier (Waters, Milford, MA) using MassLynx v4.0 software.
Statistics
All results are expressed as mean 6 SEM. GraphPad Prism 7 and JFlashcalc (developed by Dr. Michael Ossipov) are used for statistics analyses. The unpaired t test (2-tailed, for 2 groups), one-way ANOVA post hoc Tukey multiple comparisons test, or repeated-measure 2-way ANOVA post hoc Sidak, Tukey, or Fisher least significant difference multiple comparisons test is used for more than 2 groups comparison. The paired t test (2-tailed) is used for CPP data analysis. Significance is set at P , 0.05.
Results
2-261 is a potent and efficacious modulator of GABA
2-261 showed high-efficacy (.1000%) positive allosteric modulation of GABA-evoked EC 10 currents in oocytes expressing GABA A receptors without significant direct effects up to a concentration of 10,000 nM (Fig. 1A) . 2-261 elicited maximum modulation of GABA-evoked EC 10 currents in human a 4 b 3 d GABA A Rs of ;1600% (EC 50 5 265 nM) vs ;400% (EC 50 5 1000 nM) in human a 4 b 3 GABA A Rs (Fig. 1B) . 2-261 exceeded the neurosteroid allopregnanolone (ALLO) for positive modulation of a 4 b 3 d GABA A Rs in potency (520 nM) and maximum efficacy (;1400%) (Fig. 1C) . We evaluated a series of close 2-261 analogs with limited efficacy at b 1 -subunit-containing GABA A Rs (similar to 2-261) and demonstrated differential potency and efficacy for positive modulation of a 4 b 3 d GABA A Rs (Figs. 1C, D , and E). These 2-261 analogs also exhibited robust maximum modulation of b 2/3 -subunit-containing GABA A Rs (Fig. 1E) . Structure-activity analysis shows the position of 3.3. Spinal 2-261 alleviates nerve injury-induced ongoing pain and elicits enhanced release of dopamine from the nucleus accumbens
We further evaluated the potential effect of spinal 2-261 (0.2 mg/ 0.5 mL, i.t.) on inhibiting ongoing pain using the CPP assay as well as measurement of in vivo DA release from the NAc (Fig. 3) . Rats received either vehicle or 2-261 treatment paired with a specific chamber at day 14 after SNL or sham surgeries. The rats with nerve injury preferred the 2-261-paired chamber, suggesting that 2-261 provides sufficient relief of ongoing pain to promote learning (Figs. 3A and B, P , 0.05 preconditioning vs postconditioning). No preference was observed in shamoperated animals after 2-261 treatment. The lack of intrinsic reward or addictive liabilities of this compound is consistent with our previous results in naive animals. 70 The mitigation of pain aversiveness by 2-261 also results in enhanced DA release to the interstitial fluid in the NAc selectively in SNL animals (Figs.  3C and D) . The release of NAc DA increased from baseline throughout the entire collection period (4 fractions of 30 minutes each, total 2 hours, Fig. 3C ) and peaked at the second fraction. The baseline DA levels among SNL and sham-operated animals were not significantly different (0.35 6 0.021 and 0.35 6 0.02 pg/mL or 0.882 6 0.135 and 0.885 6 0.190 nM, respectively), in agreement with our previous findings. 67 We converted the data from each time point to percent change from baseline to normalize the data within each individual animal. The accumulated change of DA release across 2 hours after 2-261 administration is illustrated as area under the time effect curve showing significantly higher DA release in the SNL/2-261 group than that of SNL/Vehicle or Sham/2-261 group (Fig. 3D , P , 0.05 compared with the SNL/vehicle or Sham/2-261 group). In line with the CPP results, NAc DA levels did not change after drug administration in sham-operated rats.
Systemic administration of 2-261 reverses spinal nerve ligation-induced tactile and thermal hypersensitivity in rats
We tested the efficacy of systemic 2-261 in alleviating nerve injury-induced hypersensitivity by administering 2-261 at a dose previously demonstrated to produce anxiolytic actions (ie, 10 mg/kg, i.p.). 17 No change in baseline tactile or thermal thresholds was observed when 2-261 was administered in shamoperated controls. 2-261 significantly reversed the expected signs of neuropathic dysesthesias including tactile allodynia and thermal hyperalgesia of the affected paw in animals with SNL injury. Systemic 2-261 produced significant, albeit partial, reversal of tactile thresholds (Fig. 4A, P Note that thermal response thresholds were not elevated above preinjury baselines, suggesting that 2-261 normalized hypersensitivity but did not inhibit physiological thermal nociception. The activity of 2-261 was completely abolished by systemic pretreatment of the GABA A R antagonist gabazine at 1 mg/kg i.p., indicating that 2-261 exerts its effects by potentiating GABA A R function (Figs. 4B and D, P , 0.05 and P , 0.01 SNL/Gabazine/2-261 vs SNL/ Vehicle/2-261 treatment for tactile and thermal hypersensitivity, respectively). The long duration and equivalent brain to plasma ratio of 2-261 concentrations after 10 mg/kg i.p. administration (Fig. 4E, [2 In addition to sensory thresholds, systemic 2-261 treatment was evaluated in the CPP assay for modulation of pain aversiveness. Conditioned place preference is a measure of learning in animals to associate a context with a treatment. For this reason, rapid pharmacokinetics of drug administration is important in promoting single-trial learning for pain relief. We have shown that systemic treatments that abolish aversive states of pain can block the CPP that is produced with rapidly acting treatments (eg, i.t. clonidine, an a-adrenergic agonist). 35 Here, 2-261 blocked the CPP resulting from spinal clonidine in SNL rats such that the postconditioning with clonidine does not occur (Fig. 5, P , 0 .05 preconditioning vs postconditioning in the SNL/Vehicle group for the time spent in clonidine-paired chamber; P , 0.05 SNL/Vehicle vs SNL/2-261 group for the difference score). This result suggests that systemic 2-261 produces relief of the aversive state of ongoing pain that is sufficient to abolish motivational drive to seek a context associated with spinal clonidine. 
and E).
24 2-301 (20 mg/kg i.p.) did not show activity against tactile hypersensitivity caused by SNL at twice the dose of 2-261 after i.p. administration (Figs. 6A and B , P , 0.001 at 30 and 60 minutes postdose compared with predose (SNL) baseline or vehicle or 2-301 treatment at the same time point), consistent with the hypothesis that activity at a 4 b 3 d is essential for antihyperalgesic activity. The lack of analgesic activity of 2-301 due to limited brain penetration is unlikely because 2-301 has been previously reported to exhibit robust anxiolytic activity at 15% of the dose used in the current study via the same route of administration. 71 
Effects in HIV-related neuropathic pain
In addition to physical trauma, neuropathic pain can also result from infections, including from the HIV. HIV-related neuropathic pain is very difficult to treat, and clinical trials demonstrate that reuptake blockers are ineffective and gabapentinoids are marginally effective. 47 We therefore tested 2-261 (10 mg/kg, i. p.) in a model of HIV-related neuropathic pain to determine whether the extrasynaptic d-subunit hypothesis applied in other models of chronic pain. The HIV envelope protein, gp120 (300 ng/ 20 mL, i.t.), was injected every other day for 3 days through lumbar puncture. Long-lasting tactile allodynia was developed after 7 days postdose. Similar to its effect in the SNL trauma-induced neuropathic pain model, systemic 2-261 significantly reversed tactile allodynia in gp120-pretreated rats (Figs. 6C and D, P , 0.01 or P , 0.05 at 30 and 60 minutes postdose compared with predose (SNL) baseline or 2-301 treatment at the same time point, respectively), an observation that indicates its potential utility in the treatment of chronic pain states. As in the SNL model, we found that 2-301 (20 mg/kg i.p.) was devoid of activity in the gp120 neuropathic pain model at twice the effective dose of 2-261.
Discussion
It is not currently known whether chronic nonmalignant pain can be treated by modulators of GABA A Rs. GABAergic compounds that are currently available show (1) no evidence of effectiveness clinically (eg, BZs); (2) are not used due to intolerable side effects (for review, see Ref. 60); and (3) lack of activity at a 4 b 3 d GABA A R subtypes that may be essential for analgesia. 4, 52 Benzodiazepines have been suggested to modulate acute pain (eg, the tailflick test) in uninjured animals 49, 54, 73 based on evaluation of sensory thresholds, but this observation is not consistent with clinical experience because virtually no clinical evidence for analgesic effects of BZs exists. 12, 20, 43 One reason for this disconnect may be that preclinical studies emphasizing sensory withdrawal thresholds are complicated by subtle effects related to sedation and motor function. In addition, such reflexive measures are unlikely to capture dimensions of pain that matter most to humans (ie, pain aversiveness). 15 We have demonstrated in multiple pain models that ongoing pain can be unmasked through behavioral assessment using CPP, a procedure that pairs a context with a treatment that effectively alleviates ongoing pain. 10, 35, 40, 48, 50, 56 Relief of aversive states (eg, thirst, hunger, and cold) is a natural reward that evokes DA release within the NAc as seen in animal and human imaging studies. 2, 3 We have synthesized and previously characterized the in vitro and in vivo pharmacology of the enaminone 2-261, a GABA A R subtype-selective PAM with anxiolytic activity in mice and rats. 17, 24 Repeated systemic administration of 2-261 was demonstrated to be devoid of reinforcing properties, lacked effects on learning and memory at doses well in excess of anxiolytic doses, did not potentiate the depressant effects of ethanol, and did not induce tolerance to its anxiolytic effects. We evaluated the potential effects of 2-261 in assays that can capture affective (aversive) dimensions of pain, using painmotivated behaviors, a measure that may be viewed as "analogous" to human self-report in nonverbal animals. In addition, we have previously shown that in multiple rodent pain models that extracellular DA levels in the NAc increase in response to pain-alleviating drugs, 10, 48, 67 ie, relief of a paininduced aversive state is rewarding. In the current study, we used NAc DA efflux as an objective neurochemical correlate of behavior to establish efficacy of novel compounds in diminishing the aversive dimension of chronic pain. Spinal and systemic administration of 2-261 was effective in modulation of both sensory and affective (aversive) outcome measures, indicating that actions at a 4 b 3 d and selectivity for b 2/3 -subunit-containing GABA A Rs have utility in promoting pain relief. This notion is further reinforced by the observation that a close structural analog of 2-261, which lacks activity at a 4 b 3 d (2-301), does not induce pain relief in the models tested.
Preclinically, much attention has been focused on restoring GABA-mediated inhibition in spinal networks that may be diminished in experimental models of neuropathic pain as a way to develop new pain therapeutics. Selective reduction of protein expression of spinal GABA A d subunits has been shown after peripheral nerve injury. 27 Moreover, enhanced GABA A d-subunit activity blunts the initiation and maintenance of spinal long-term potentiation to ameliorate central sensitization of nociceptive behaviors. 41 However, significant pain-mitigating effects may be achieved by enhancing GABA A d-subunit activity in regions of the nervous system beyond the spinal cord and must be considered in the evaluation of the potential of this target for treatment of pain. In this regard, Heinricher et al. 22 have administered nonsubunit-selective GABA A R agonists within the rostral ventromedial medulla (RVM), a major site of descending pain modulation that is engaged by many clinically effective pain drugs (eg, opiates and reuptake blockers), and showed hyperalgesic effects. Hyperalgesia from direct application of GABA A R agonists onto the RVM may result from specific inhibition of OFFcells normally responsible for feedback loops that buffer pain signals through the RVM. 7, 8, 23 Although this confound may initially appear as a limitation of the utility of compounds administered by the systemic route, our data indicate that systemic administration of 2-261 does not produce hyperalgesia at doses associated with pain relief. In addition, increased inhibition within the rostral anterior cingulate cortex, an area believed to integrate the aversive features of pain, 31, 32, 56 produces CPP selectively in injured rats. 56 These observations are consistent with the systemic activity of 2-261 in producing CPP in neuropathic rats, suggesting that modulation of pain aversiveness within supraspinal networks in other brain regions that express a 4 , b 2 , and d GABA A subunits such as the thalamus may additionally contribute to a nonspinal site of action of b 2/3 -subunitselective GABA A R PAMs. 30, 53 In addition, we found that spinal 2-261 reversed evoked hyperalgesia in SNL rats without promoting increases in sensory thresholds in sham-operated rats (ie, did not elicit analgesia). The antihyperalgesic actions of spinal 2-261 were accompanied by an increase in NAc DA release selectively in rats with neuropathic pain suggesting the reward of pain relief. The lack of CPP or DA efflux after 2-261 treatment in shamoperated rats indicates that spinal 2-261 is not intrinsically rewarding. Thus, the mechanism associated with 2-261 appears unlikely to be associated with abuse potential of available analgesics such as opioids. In addition, the high brain penetration feature of molecules similar to 2-261 may allow for actions at both supraspinal and spinal levels. Activity at both supraspinal and spinal sites of these molecules might therefore result in site-site synergy, a possibility that requires further experimentation. If true, such site-site synergy would potentially allow their use for treatment of pain at doses that are increasingly separable from those producing side effects (ie, increased therapeutic index).
Patients with chronic pain often suffer from pain comorbid with anxiety. The development of novel a 4 b 3 d-active, b 2/3 -subunitpreferring GABA A R PAMs that avoid the side effects of the traditional agonist BZs suggests an innovative profile of compounds that may produce pain modulation together with antianxiety effects. Thus, combined pain relief and anxiolytic actions within a single molecule may be a highly desirable mechanism that may provide clinical benefit.
Finally, we note that the successful association of druginduced pain relief with the paired chamber in injured rats suggests that spinal 2-261 does not lead to detectable impairment of learning and memory, which is consistent with our earlier observations on cognitive function. 70 Our data collectively indicate that GABA A b 2/3 -subtype-selective PAMs with corresponding efficacy at a 4 b 3 d GABA A Rs and a benign side-effect profile represent a promising new target for the development of novel analgesics to treat chronic pain.
